Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Chemotherapy | Children | Lymphoma | Non-Hodgkin's Lymphoma | Pediatrics | Pharmaceuticals | Rituxan | Study